Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.

Aalhate, Mayur; Mahajan, Srushti; Singh, Hoshiyar; Guru, Santosh Kumar; Singh, Pankaj Kumar

Aalhate, Mayur; Mahajan, Srushti; Singh, Hoshiyar; Guru, Santosh Kumar; Singh, Pankaj Kumar.

Afiliação

Aalhate M; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India.
Mahajan S; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India.
Singh H; Department of Biological Science, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
Guru SK; Department of Biological Science, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
Singh PK; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India. pankajksingh3@gmail.com.

Drug Deliv Transl Res ; 13(6): 1621-1653, 2023 06.

Article em En | MEDLINE | ID: mdl-36795198

Assuntos

Neoplasias da Mama; Humanos; Feminino; Neoplasias da Mama/tratamento farmacológico; Receptores de Estrogênio/metabolismo; Receptores de Estrogênio/uso terapêutico; Nanomedicina

Palavras-chave

Breast cancer; Estrogen receptor; Gene delivery; Nanocarriers; Targeted therapies

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Drug Deliv Transl Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Índia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google